Literature DB >> 19737944

Prevention of progression in monoclonal gammopathy of undetermined significance.

S Vincent Rajkumar1.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a common premalignant plasma cell proliferative disorder with a lifelong risk of progression to multiple myeloma. Because myeloma is an incurable malignancy, strategies to delay or prevent progression in high-risk patients are of considerable importance.

Entities:  

Mesh：

Year:  2009        PMID： 19737944      PMCID： PMC2759099          DOI： 10.1158/1078-0432.CCR-09-1575

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

1.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

2.  The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker.

Authors:  Terry Golombick; Terrence H Diamond; Vladimir Badmaev; Arumugam Manoharan; Rajeev Ramakrishna
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

3.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

Review 6.  Chromosome translocations in multiple myeloma.

Authors:  P L Bergsagel; W M Kuehl
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

7.  Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.

Authors:  Alok C Bharti; Shishir Shishodia; James M Reuben; Donna Weber; Raymond Alexanian; Saroj Raj-Vadhan; Zeev Estrov; Moshe Talpaz; Bharat B Aggarwal
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

Review 8.  Pathogenesis of myeloma bone disease.

Authors:  G D Roodman
Journal:  Leukemia       Date:  2008-11-27       Impact factor: 11.528

9.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

Authors:  Ola Landgren; Jerry A Katzmann; Ann W Hsing; Ruth M Pfeiffer; Robert A Kyle; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew A Adjei; Dirk R Larson; Angela Dispenzieri; L Joseph Melton; Lynn R Goldin; Mary L McMaster; Neil E Caporaso; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

10.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.

Authors:  Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Shimera Kamihira; Masao Tomonaga
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616
View more
  13 in total

Review 1.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

Review 2.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

Review 3.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution.

Authors:  A J M Vermorken; J Zhu; W J M VAN DE Ven; Y Cui; J P Fryns
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

Review 5.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

Review 6.  Treatment of multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

7.  Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.

Authors:  Terry M Therneau; Robert A Kyle; L Joseph Melton; Dirk R Larson; Joanne T Benson; Colin L Colby; Angela Dispenzieri; Shaji Kumar; Jerry A Katzmann; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-08-07       Impact factor: 7.616

Review 8.  Smoldering multiple myeloma requiring treatment: time for a new definition?

Authors:  Angela Dispenzieri; A Keith Stewart; Asher Chanan-Khan; S Vincent Rajkumar; Robert A Kyle; Rafael Fonseca; Prashant Kapoor; P Leif Bergsagel; Arleigh McCurdy; Morie A Gertz; Martha Q Lacy; John A Lust; Stephen J Russell; Steven R Zeldenrust; Craig Reeder; Vivek Roy; Francis Buadi; David Dingli; Suzanne R Hayman; Nelson Leung; Yi Lin; Joseph Mikhael; Shaji K Kumar
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

9.  Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?

Authors:  Normann Steiner; Angelika Schwärzler; Georg Göbel; Wolfgang Löscher; Julia Wanschitz; Eberhard Gunsilius
Journal:  Oncotarget       Date:  2017-01-17

10.  High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

Authors:  G Bianchi; R A Kyle; D R Larson; T E Witzig; S Kumar; A Dispenzieri; W G Morice; S V Rajkumar
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.